Flt3 ligand

A novel cytokine prevents allergic asthma in a mouse model

Devendra K. Agrawal, Michael T. Hopfenspirger, Jennifer Chavez, James E. Talmadge

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

Original languageEnglish
Pages (from-to)2081-2089
Number of pages9
JournalInternational Immunopharmacology
Volume1
Issue number12
DOIs
StatePublished - 2001

Fingerprint

Asthma
Cytokines
Ovalbumin
Bronchoalveolar Lavage Fluid
Interleukin-12
T-Lymphocytes
Methacholine Chloride
Interleukin-5
Hematopoietic Stem Cells
Eosinophils
Interleukin-4
Dendritic Cells
Immunoglobulin E
Intercellular Signaling Peptides and Proteins
Therapeutics
flt3 ligand protein
Phenotype
Serum

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology

Cite this

Flt3 ligand : A novel cytokine prevents allergic asthma in a mouse model. / Agrawal, Devendra K.; Hopfenspirger, Michael T.; Chavez, Jennifer; Talmadge, James E.

In: International Immunopharmacology, Vol. 1, No. 12, 2001, p. 2081-2089.

Research output: Contribution to journalArticle

Agrawal, Devendra K. ; Hopfenspirger, Michael T. ; Chavez, Jennifer ; Talmadge, James E. / Flt3 ligand : A novel cytokine prevents allergic asthma in a mouse model. In: International Immunopharmacology. 2001 ; Vol. 1, No. 12. pp. 2081-2089.
@article{6de6f373b72e48c68f15aa6dfc7fe99a,
title = "Flt3 ligand: A novel cytokine prevents allergic asthma in a mouse model",
abstract = "Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.",
author = "Agrawal, {Devendra K.} and Hopfenspirger, {Michael T.} and Jennifer Chavez and Talmadge, {James E.}",
year = "2001",
doi = "10.1016/S1567-5769(01)00122-9",
language = "English",
volume = "1",
pages = "2081--2089",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Flt3 ligand

T2 - A novel cytokine prevents allergic asthma in a mouse model

AU - Agrawal, Devendra K.

AU - Hopfenspirger, Michael T.

AU - Chavez, Jennifer

AU - Talmadge, James E.

PY - 2001

Y1 - 2001

N2 - Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

AB - Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-γ levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.

UR - http://www.scopus.com/inward/record.url?scp=0034774974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034774974&partnerID=8YFLogxK

U2 - 10.1016/S1567-5769(01)00122-9

DO - 10.1016/S1567-5769(01)00122-9

M3 - Article

VL - 1

SP - 2081

EP - 2089

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 12

ER -